NASDAQ:THTX - Nasdaq - CA88338H7040 - Common Stock - Currency: USD
THTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. There are concerns on the financial health of THTX while its profitability can be described as average. THTX is not valued too expensively and it also shows a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -6.57% | ||
ROE | N/A | ||
ROIC | 45.67% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 13.89% | ||
PM (TTM) | N/A | ||
GM | 78.97% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Altman-Z | -7.14 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.08 | ||
Quick Ratio | 0.88 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 10.09 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 10.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2.53
+0.03 (+1.2%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 10.09 | ||
P/S | 1.31 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | N/A | ||
P/tB | N/A | ||
EV/EBITDA | 10.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -6.57% | ||
ROE | N/A | ||
ROCE | 57.81% | ||
ROIC | 45.67% | ||
ROICexc | 57.36% | ||
ROICexgc | N/A | ||
OM | 13.89% | ||
PM (TTM) | N/A | ||
GM | 78.97% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | N/A | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 3.04 | ||
Cap/Depr | 424.28% | ||
Cap/Sales | 13.09% | ||
Interest Coverage | 1.49 | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.08 | ||
Quick Ratio | 0.88 | ||
Altman-Z | -7.14 |